Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai’s Cardio Suite at AHA 2026

Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai’s Cardio Suite at AHA 2026

Studies from Beth Israel Deaconess and the University of Colorado highlight how AI-ECG can help clinicians identify suspected cardiac disease from routine ECGs

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that two research abstracts evaluating its AI-powered electrocardiogram (AI-ECG) technology within the Viz Cardio Suite have been accepted for presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) meeting, held in conjunction with the American Heart Association’s Scientific Sessions 2026 in Chicago. Both studies focus on Viz HCM, the suite’s AI-ECG algorithm for detecting hypertrophic cardiomyopathy (HCM), a frequently underdiagnosed form of cardiac disease.

Despite significant advances in treatment for hypertrophic cardiomyopathy (HCM), an estimated 85% of patients may remain undiagnosed, underdiagnosed, or misdiagnosed,1 highlighting the need for better tools to identify patients who could benefit from earlier intervention and specialty care. The Viz HCM solution was developed as part of a multi-year agreement between Viz.ai and Bristol Myers Squibb (NYSE: BMY) aimed at transforming how HCM is identified and managed. Viz HCM was the first FDA-cleared AI algorithm designed to help clinicians detect signs of HCM using a standard 12-lead ECG.2

The new studies, conducted by investigators at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, and the University of Colorado, highlight AI-ECG technology's potential to identify patients who may be missed by traditional detection methods.

“We've been using ECGs for decades, but we're still discovering just how much they can tell us,” said Jordan B. Strom, MD, MSc, of Beth Israel Deaconess Medical Center. “In our study, Viz HCM added meaningful information beyond standard ECG interpretation in identifying patients with suspected disease. This opens up exciting possibilities for how we use a test we already rely on every day to better evaluate and care for patients.”

With 21 clinical abstracts and studies presented to date, Viz HCM has been evaluated across academic and real-world clinical settings, contributing to a growing body of evidence supporting its clinical utility.

“Most patients with HCM are never diagnosed, and the ones who are often wait years. What these two studies show is that the ECGs that health systems are already collecting contain the signal to change that,” said Tim Showalter, MD, Chief Medical Officer at Viz.ai. “Collaborations like these are essential to advancing our understanding of what’s possible with the technology within the Viz Cardio Suite and bringing these innovations into everyday clinical care, where they can make a meaningful difference for patients.”

Key findings from the studies being presented at the event include:

• “Artificial Intelligence Electrocardiogram Analysis Compared with Diagnosis Code-Based Ascertainment for Hypertrophic Cardiomyopathy in a Real-World Electronic Health Record Cohort” — Conducted by researchers at the University of Colorado, the study analyzed ECGs from more than 29,000 patients and found that nearly 40% of those flagged by Viz HCM for suspected HCM had no corresponding diagnosis code in their medical records. The findings suggest AI-ECG may complement traditional diagnosis-code-based approaches to identifying patients who might otherwise never reach a specialist for further evaluation.
• “Artificial Intelligence-Enabled Algorithm for Detection of Hypertrophic Cardiomyopathy Compared with a Standard Electrocardiogram” — In a Beth Israel Deaconess Medical Center study, the Viz AI-ECG algorithm identified suspected HCM beyond what standard ECG measurements could, and patients flagged by the algorithm had a 2.68-fold higher hazard of adverse clinical events.

To learn more about Viz.ai and the technology available within the Viz Cardio Suite, visit https://www.viz.ai/cardio.

About Viz.ai
Viz.ai is the leader in building and deploying AI-powered Care Pathways and helping doctors do their work. The Viz Platform is deployed in 2,000 hospitals across the United States and trusted by many of the leading life sciences companies. The platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai.

Funding
Support for the current study provided by MyoKardia, Inc., a Bristol Myers Squibb company, through a funding agreement with Viz.ai.

References

1. Maron MS et al., “Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States,” Am J Cardiol 2016;117(10):1651–1654
2. FDA De Novo DEN230003, August 2023.

Media Contact
Caroline Rueve
viz.ai@solcomms.co

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106195617/en/